Scarica l'app Stockscreener
0.4701
6.04%
-0.0302
Precedente Chiudi:
$0.5003
Aprire:
$0.491
Volume 24 ore:
456.61K
Relative Volume:
1.60
Capitalizzazione di mercato:
$40.63M
Reddito:
-
Utile/perdita netta:
$-20.31M
Rapporto P/E:
-1.7773
EPS:
-0.2645
Flusso di cassa netto:
$-21.07M
1 W Prestazione:
-9.46%
1M Prestazione:
-17.24%
6M Prestazione:
-52.03%
1 anno Prestazione:
-58.40%
Intervallo 1D:
$0.4693
$0.50
Intervallo di 1 settimana:
$0.4693
$0.54
Portata 52W:
$0.4679
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Nome
Oncolytics Biotech Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ONCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.4701 | 46.68M | 0 | -20.31M | -21.07M | -0.2645 |
|
ONC
Beigene Ltd Adr
|
228.82 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.14 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2256 | 38.69M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.90 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
69.77 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-06 | Iniziato | Maxim Group | Buy |
| 2021-02-17 | Iniziato | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
Oncolytics Biotech’s Earnings Call: Optimism Amid Challenges - TipRanks
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Oncolytics Biotech Reports Q1 Results and Clinical Progress - TipRanks
Oncolytics Biotech Reports Q1 2025 Financial Results - TipRanks
Oncolytics Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oncolytics Biotech Reports Promising Q1 Results and Advances in Cancer Treatment - TipRanks
Breakthrough Cancer Trial: Oncolytics Achieves 33% Response Rate in Anal Cancer, Reports Strong Q1 Progress - Stock Titan
How To Trade (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights - Kilgore News Herald
Oncolytics Biotech Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
(ONC) Trading Strategy and Analysis (ONC:CA) - news.stocktradersdaily.com
(ONC) Stock Analysis and Trading Signals (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech to Discuss Q1 2025 Financial Results on May 14 - TipRanks
Stocks In Play: Oncolytics Biotech® Inc. By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Inc. - Baystreet.ca
Stocks in play: Oncolytics Biotech® Inc. - The Globe and Mail
Oncolytics Biotech to Discuss Q1 Financial Results and Operational Highlights - TipRanks
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ONCY Stock News - GuruFocus
(ONC) Risk-Controlled Trading Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer - ACCESS Newswire
(ONC) Technical Data (ONC:CA) - news.stocktradersdaily.com
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - Longview News-Journal
Oncolytics Biotech, Inc. to Host Earnings Call - ACCESS Newswire
(ONC) Technical Patterns and Signals (ONC:CA) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
(ONC) Stock Trading Blueprint (ONC:CA) - news.stocktradersdaily.com
Small-cap cancer therapy innovator raises $20M in flexible funding - MSN
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics to Present New Pancreatic Cancer Data at Oncology Meeting Next Month - marketscreener.com
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at AS - GuruFocus
Oncolytics Biotech to Present Promising Pancreatic Cancer Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action - Barchart.com
(ONC) Long Term Investment Analysis (ONC:CA) - news.stocktradersdaily.com
Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire) - Aktiellt
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt
Buzz on the Bullboards: Energy, cannabis, and Biotech Shine on the TSX | 2025-04-17 | Investing News - Stockhouse
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech : reg; Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer - marketscreener.com
Oncolytic Virus Therapy Market Size, Share and Strategic - openPR.com
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - The Malaysian Reserve
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers - Eastern Progress
Oncolytics Biotech Inc Azioni (ONCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.08%
4.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):